Claims for Patent: 9,199,977

Summary for Patent: 9,199,977

Title:	Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Abstract:	An object is to provide means for improving the solubility of luliconazole. Disclosed is a crystal of luliconazole wherein the crystal has such a crystal habit that (021) plane is a specific crystal growth plane.
Inventor(s):	Masuda; Takaaki (Kanagawa, JP)
Assignee:	POLA PHARMA INC. (Tokyo, JP) NIHON NOHYAKU CO., LTD. (Tokyo, JP)
Application Number:	13/988,003
Patent Claims:	1. A crystal of luliconazole represented by the following formula, wherein the crystal is recrystallized from alcohol which optionally contains water, wherein the crystal has such a crystal habit that (021) plane is a specific crystal growth plane: ##STR00003## 2. The crystal according to claim 1, wherein I.sub.(021)) with respect to a sum total of I.sub.(001), I.sub.(100), I.sub.(10-1), I.sub.(011), I.sub.(110), I.sub.(11-1), I.sub.(10-2), I.sub.(11-2), I.sub.(020), I.sub.(021), I.sub.(20-2), I.sub.(121), I.sub.(013), I.sub.(11-3), and I.sub.(221) is not less than 1/3, provided that in relation to the diffraction peaks detected in a range of 2.theta.=5 to 35.degree. in a powder X-ray diffractometry using CuK.alpha. radiation, the integrated intensities of the diffraction peaks, which correspond to the (001), (100), (10-1), (011), (110), (11-1), (10-2), (11-2), (020), (021), (20-2), (121), (013), (11-3), and (221) planes, are designated as I.sub.(001), I.sub.(100), I.sub.(10-1), I.sub.(011), I.sub.(110), I.sub.(11-1), I.sub.(10-2), I.sub.(11-2), I.sub.(020), I.sub.(021), I.sub.(20-2), I.sub.(121), I.sub.(013), I.sub.(11-3), and I.sub.(221) respectively. 3. The crystal according to claim 1, wherein the crystal has a monoclinic crystal system. 4. An active pharmaceutical ingredient, containing the crystal as defined in claim 1. 5. A method for producing a pharmaceutical composition, comprising a step of dissolving, in a solvent, the crystal as defined in claim 1.